Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
Future Oncology · 2023-11 · 19 (34) · 2297-2311
DOI: 10.2217/fon-2022-1317 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Future Oncology, online erschienen am 27.07.2023. Verfasst von Thomas G Martin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Janssen Global Services, LLC, Janssen Global Services LLC.
Abstract (Originalsprache)
Cilta-cel, a BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma, was approved in USA on 28 February 2022, for patients with relapsed or refractory disease who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Approval in the EU followed for patients with ≥3 prior therapies. At median 28-month follow-up, the pivotal CARTITUDE-1 trial showed a 98% response rate (83% stringent complete response); median progression-free survival had not been reached, and adverse events could be managed with supportive therapy. Cilta-cel efficacy and safety in earlier lines of therapy, and its optimal sequencing in a complex treatment landscape are important areas of investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94158, USA.
- Janssen Research & Development, Raritan, NJ 08869, USA.
- Legend Biotech USA Inc., Somerset, NJ 08873, USA.
- Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
ORCID-Profile: Saad Z Usmani
Förderung
- Janssen Global Services, LLC
- Janssen Global Services LLC
Zitieren
APA
Martin, T. G., Madduri, D., Pacaud, L., & Usmani, S. Z. (2023). Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Future Oncology, 19(34), 2297-2311. https://doi.org/10.2217/fon-2022-1317
Vancouver
Martin TG, Madduri D, Pacaud L, Usmani SZ. Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma. Future Oncology. 2023;19(34):2297-2311. doi:10.2217/fon-2022-1317
BibTeX
@article{Martin2023,
author = {Martin, Thomas G and Madduri, Deepu and Pacaud, Lida and Usmani, Saad Z},
title = {Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma},
journal = {Future Oncology},
year = {2023},
volume = {19},
number = {34},
pages = {2297--2311},
doi = {10.2217/fon-2022-1317}
}
EUVIMED